SEEL vs. BDRX, PRFX, TCBP, TFFP, SRNE, SMFL, BLPH, NEXI, HSTO, and VAXX
Should you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include Biodexa Pharmaceuticals (BDRX), PainReform (PRFX), TC Biopharm (TCBP), TFF Pharmaceuticals (TFFP), Sorrento Therapeutics (SRNE), Smart for Life (SMFL), Bellerophon Therapeutics (BLPH), NexImmune (NEXI), Histogen (HSTO), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical products" industry.
Seelos Therapeutics vs.
Seelos Therapeutics (NASDAQ:SEEL) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
23.4% of Seelos Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 1.1% of Seelos Therapeutics shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Seelos Therapeutics. MarketBeat recorded 1 mentions for Biodexa Pharmaceuticals and 0 mentions for Seelos Therapeutics. Seelos Therapeutics' average media sentiment score of 0.00 equaled Biodexa Pharmaceuticals'average media sentiment score.
Seelos Therapeutics received 70 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 66.36% of users gave Seelos Therapeutics an outperform vote.
Seelos Therapeutics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.
Biodexa Pharmaceuticals has a consensus price target of $200.00, suggesting a potential upside of 4,492.42%. Given Biodexa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Biodexa Pharmaceuticals is more favorable than Seelos Therapeutics.
Biodexa Pharmaceuticals has lower revenue, but higher earnings than Seelos Therapeutics.
Seelos Therapeutics has a net margin of 203.13% compared to Biodexa Pharmaceuticals' net margin of 0.00%.
Summary
Biodexa Pharmaceuticals beats Seelos Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Seelos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seelos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SEEL) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SEEL Stock Alerts